One key main selling point of the EmbraceMini is its ultra-compact design. It delivers exceptional wearability, comfort, and high-quality data without compromising client or participant needs. It offers effortless and non-invasive data collection while ensuring optimal patient experience at all times.
It functions by wirelessly transmitting sensor data to the FDA-cleared Empatica Health Monitoring Platform, which enables the continuous analysis and extraction of precise digital biomarkers from clinical trial participants.
Simone Tognetti, Chief Technical Officer and Co-Founder of Empatica explained that this technology fills a gap in the life sciences market. She said: “Most devices adopted in clinical trials today are too bulky, or just not fit for purpose. Wearability is crucial for the success of the study, so our goal with EmbraceMini was to make a compact, beautiful wearable that offers the same data quality and range as EmbracePlus, without ‘competing’ with people’s favourite watches or accessories for room on their wrist.”
The EmbraceMini is just 12mm thick and 14mm wide, making it the smallest wrist-worn actigraphy device for clinical research in the world. Its long battery life can achieve at least 7 days of continuous data collection.
Despite its small size, the EmbraceMini can sub-consciously track over 200 digital measures, including digital biomarkers across sleep, physical activity, and light exposure. These play a vital role as digital endpoints in trials on sleep disorders, movement disorders, obesity, depression, and pain.
The EmbraceMini works seamlessly with Empatica’s software but can also be integrated into existing Clinical Trial Management Systems using a Cloud API, illustrating its flexibility. Finally, EmbraceMini is expected to receive FDA clearance in late 2025.
